Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Novartis
Queensland Health
Harvard Business School
Deloitte
McKinsey
Argus Health
Cipla
Boehringer Ingelheim
McKesson

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,988,998

« Back to Dashboard

Which drugs does patent 7,988,998 protect, and when does it expire?

Patent 7,988,998 protects RYZOLT and is included in one NDA.

This patent has fifty-one patent family members in twenty-six countries.
Summary for Patent: 7,988,998
Title:Sustained-release tramadol formulations with 24-hour efficacy
Abstract: A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.
Inventor(s): Lenaerts; Vincent (Beaconsfield, CA), Ouadji-Nijki; Patricia Laure (Montreal, CA), Bacon; Jonathan (Montreal, CA), Ouzerourou; Rachid (Montreal, CA), Gervais; Sonia (Laval, CA), Rahmouni; Miloud (Dollars-des Ormeaux, CA), Smith; Damon (St-Laurent, CA)
Assignee: Labopharm Inc. (Quebec, CA) Labopharm Europe Limited (Dublin, IE) Labopharm (Barbados) Limited (Hastings, Christ Church, BB)
Application Number:11/112,008
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation; Device;

Drugs Protected by US Patent 7,988,998

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Purdue Pharma RYZOLT tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021745-001 Dec 30, 2008 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma RYZOLT tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021745-002 Dec 30, 2008 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma RYZOLT tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021745-003 Dec 30, 2008 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,988,998

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,009,047,345 ➤ Sign Up
2,010,151,022 ➤ Sign Up
8,487,002 Controlled-release compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,988,998

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045972 ➤ Sign Up
Argentina 045973 ➤ Sign Up
Austria 390128 ➤ Sign Up
Austria 400819 ➤ Sign Up
Australia 2003275854 ➤ Sign Up
Australia 2003275855 ➤ Sign Up
Brazil 0315657 ➤ Sign Up
Brazil 0315659 ➤ Sign Up
Canada 2503155 ➤ Sign Up
Canada 2503361 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Queensland Health
Chinese Patent Office
Teva
Citi
QuintilesIMS
Fish and Richardson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot